Abstract
Macromolecule drugs designed against specific target proteins/receptors have been applied in combination therapies, especially for complex and related diseases such as cancer for synergistic efficacy and alleviation of side effects. Protein therapeutics are typically measured using ligand binding assays (LBA). Evaluating the specificity and selectivity of LBA against their target proteins or in instances where concomitantly administered drugs are given was brought up during a conversation at the 3rd American Association of Pharmaceutical Scienctists/US Food and Drug Administration Bioanalytical Workshop but was not discussed at the meeting sessions. The purpose of this article is to discuss the challenges related to this issue and present a few approaches and experiences to elicit further discussions.
Specificity and selectivity tests should be based on the anticipated levels of the individual therapeutics with reference to the dosing regimens defined in the clinical study protocol. When the concomitantly administered compound is available as a pure or well-defined material, various concentrations from zero to above the expected high levels are added to validation samples of the protein therapeutics to assess specificity. Recovery results from spiked samples of target patient populations on concomitant medications can also be compared with those from normal individuals for selectivity. If the drug has an endogenous counterpart, the baseline concentrations of each lot should be subtracted from the test samples in the selectivity assessment. This article illustrates a flexible approach to evaluating specificity and selectivity on samples from target patient populations receiving multiple medications.
Keywords: Binding assay, protein therapeutics, concomitants, specificity, selectivity
Full Text
The Full Text of this article is available as a PDF (685.0 KB).
References
- 1.Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006;12:600–607. doi: 10.1158/1078-0432.CCR-05-1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412–1419. doi: 10.1002/art.20221. [DOI] [PubMed] [Google Scholar]
- 3.Ohta M, Konno H, Tanaka T, et al. Effect of combination therapy with matrix metalloproteinase inhibitor MMI-166 and mitomycin C on the growth and liver metastasis of human colon cancer. Cancer Sci. 2001;92:688–695. doi: 10.1111/j.1349-7006.2001.tb01149.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:S73–S77. [PubMed] [Google Scholar]
- 5.de la Gándara J, Rojo JE, Ros S, et al. Neuropharmacological basis of combining antidepressants. Acta Psychiatr Scand. 2005;112:11–36. doi: 10.1111/j.1600-0447.2005.00675.x. [DOI] [PubMed] [Google Scholar]
- 6.Smorenburg CH, Sparreboom A, Bontenbal M, et al. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer. 2001;37:2310–2323. doi: 10.1016/S0959-8049(01)00309-4. [DOI] [PubMed] [Google Scholar]
- 7.Manni A, Trout D, Verderame MF, et al. Effect of alpha-difluoremethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. Breast Cancer Res Treat. 2001;68:139–146. doi: 10.1023/A:1011923630307. [DOI] [PubMed] [Google Scholar]
- 8.Heeschen C, Dimmeler S, Hamm CW, et al. prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003;107:524–530. doi: 10.1161/01.CIR.0000048183.37648.1A. [DOI] [PubMed] [Google Scholar]
- 9.Akil I, Yuksel H, Urk V, et al. Biochemical markers of bone metabolism and calciuria with inhaled budesonide therapy. Pediatr Nephrol. 2004;19:511–515. doi: 10.1007/s00467-004-1418-z. [DOI] [PubMed] [Google Scholar]
- 10.Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006;54:298–302. doi: 10.1016/j.phrs.2006.06.006. [DOI] [PubMed] [Google Scholar]
- 11.US Department of Health and Human Services . Guidance for the Industry; Bioanalytical Method Validation. Washington, DC: US Department of Health and Human Services, FDA, CDER, and CVM; 2001. [Google Scholar]
- 12.Shah VP, Midha KK, Dighe S, et al. Analytical method validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci. 1992;81:309–312. doi: 10.1002/jps.2600810324. [DOI] [Google Scholar]
- 13.Shah VP, Midha KK, Dighe S, et al. Bioanalytical method validation—a revisit with a decade of progress. Pharm Res. 2000;17:1551–1557. doi: 10.1023/A:1007669411738. [DOI] [PubMed] [Google Scholar]
- 14.Findlay JWA, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249–1273. doi: 10.1016/S0731-7085(99)00244-7. [DOI] [PubMed] [Google Scholar]
- 15.Miller K, Bowsher RR, Celniker A, et al. Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res. 2001;18:1373–1383. doi: 10.1023/A:1013062600566. [DOI] [PubMed] [Google Scholar]
- 16.DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885–1900. doi: 10.1023/B:PHAM.0000003390.51761.3d. [DOI] [PubMed] [Google Scholar]